A phase II study of doxorubicin plus paclitaxel followed by weekly paclitaxel as neoadjuvant chemotherapy for breast cancer (SBCCSG-07)

被引：0
|
作者：
Inoue, K.
Takei, H.
Kurozumi, M.
Futsuhara, K.
Kai, T.
Kuroda, T.
Ueda, S.
Miyake, H.
Hakamada, Y.
Suemasu, K.
Tabei, T.
机构：
[1] Saitama Canc Ctr, Saitama, Japan
[2] Jichi Med Sch, Omiya Med Ctr, Saitama, Japan
[3] Omiya Kyoritsu Hosp, Saitama, Japan
[4] Sekishindo Hosp, Saitama, Japan
[5] Natl Def Med, Saitama, Japan
[6] Kasukabe City Hosp, Saitama, Japan
[7] Toda Chuo Gen Hosp, Saitama, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11103
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Multicenter phase II study of weekly paclitaxel followed by doxorubicin plus paclitaxel as neoadjuvant chemotherapy for triple negative breast cancer (SBCCSG#12, Saitama Breast Cancer Clinical Study Group, Japan)
    Nagai, S. E.
    Inoue, K.
    Futsuhara, K.
    Saito, T.
    Sakurai, T.
    Takei, H.
    Kai, T.
    Kurosumi, M.
    Tabei, T.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S468 - S469
  • [2] Phase II study of AC (doxorubicin and cyclophosphamide) followed by weekly paclitaxel as neoadjuvant chemotherapy in operable patients with primary breast cancer
    Iwase, S.
    Yamamoto, D.
    Kitamura, K.
    Odagiri, H.
    Teramoto, S.
    Ohtani, S.
    Doi, T.
    Kinebuchi, K.
    Kuroda, Y.
    Nagumo, Y.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] A randomized, multicenter phase III trial comparing doxorubicin plus cyclophosphamide followed by paclitaxel or doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for high-risk breast cancer
    Loesch, D. M.
    Greco, F.
    O'Shaughnessy, J.
    Hainsworth, J. D.
    Vukelja, S. J.
    Sandbach, J.
    Boehm, K. A.
    Ilegbodu, D.
    Asmar, L.
    Robert, N. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] Phase III Multicenter Trial of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel Compared With Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel As Adjuvant Therapy for Women With High-Risk Breast Cancer
    Loesch, David
    Greco, F. Anthony
    Senzer, Neil N.
    Burris, Howard A.
    Hainsworth, John D.
    Jones, Stephen
    Vukelja, Svetislava J.
    Sandbach, John
    Holmes, Frankie
    Sedlacek, Scot
    Pippen, John
    Lindquist, Deborah
    McIntyre, Kristi
    Blum, Joanne L.
    Modiano, Manuel R.
    Boehm, Kristi A.
    Zhan, Feng
    Asmar, Lina
    Robert, Nicholas
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18) : 2958 - 2965
  • [5] A randomized, multicenter phase III trial comparing regimens of doxorubicin plus cyclophosphamide followed by paclitaxel or doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for patients with high risk breast cancer
    Loesch, D
    Greco, FA
    O'Shaughnessy, J
    Asmar, L
    Senzer, NN
    Burris, HA
    Hainsworth, JD
    Vukelja, S
    Sandbach, J
    Holmes, F
    Sedlacek, S
    Lindquist, D
    Pippen, J
    Olivares, J
    Boehm, KA
    Zhan, F
    Robert, N
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S16 - S17
  • [6] Doxorubicin (Adriamycin, A) plus paclitaxel (T) followed by weekly paclitaxel (wT) as primary chemotherapy for women with locally advanced breast cancer (LABC).
    Zambetti, M
    Mariani, G
    Citterio, G
    Valagussa, P
    Greco, M
    Tomasic, G
    Lozza, L
    Piotti, P
    Gianni, L
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S110 - S110
  • [7] Neoadjuvant chemotherapy with low dose of pegylated liposomal doxorubicin plus weekly paclitaxel in operable and locally advanced breast cancer
    Rossi, David
    Baldelli, Anna Maria
    Casadei, Virginia
    Fedeli, Stefano Luzi
    Alessandroni, Paolo
    Catalano, Vincenzo
    Giordani, Paolo
    Ceccolini, Monica
    Graziano, Francesco
    Catalano, Giuseppina
    [J]. ANTI-CANCER DRUGS, 2008, 19 (07) : 733 - 737
  • [8] Efficacy and feasibility of neoadjuvant chemotherapy with FEC 100 followed by weekly paclitaxel for operable breast cancer
    Kawajiri, Hidemi
    Takashima, Tsutomu
    Onoda, Naoyoshi
    Kashiwagi, Shinichiro
    Noda, Satoru
    Ishikawa, Tetsurou
    Wakasa, Kenichi
    Hirakawa, Kosei
    [J]. ONCOLOGY LETTERS, 2012, 4 (04) : 612 - 616
  • [9] Weekly paclitaxel and cisplatin as neoadjuvant chemotherapy with locally advanced breast cancer: a prospective, single arm, phase II study
    Zhou, Liheng
    Xu, Shuguang
    Yin, Wenjin
    Lin, Yanpin
    Du, Yueyao
    Jiang, Yiwei
    Wang, Yaohui
    Zhang, Jie
    Wu, Ziping
    Lu, Jinsong
    [J]. ONCOTARGET, 2017, 8 (45) : 79305 - 79314
  • [10] Epirubicin, cyclophosphamide and weekly paclitaxel as neoadjuvant chemotherapy for stage II and III breast cancer
    David Aguiar Bujanda
    Uriel Bohn Sarmiento
    Miguel Ángel Cabrera Suárez
    Marta Pavcovich Ruiz
    Miguel Ángel Limeres González
    José Aguiar Morales
    [J]. Journal of Cancer Research and Clinical Oncology, 2006, 132 : 332 - 338
12345